U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C14H20N2O3.ClH
Molecular Weight 300.781
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROPACETAMOL HYDROCHLORIDE

SMILES

Cl.CCN(CC)CC(=O)OC1=CC=C(NC(C)=O)C=C1

InChI

InChIKey=WGTYJNGARJPYKG-UHFFFAOYSA-N
InChI=1S/C14H20N2O3.ClH/c1-4-16(5-2)10-14(18)19-13-8-6-12(7-9-13)15-11(3)17;/h6-9H,4-5,10H2,1-3H3,(H,15,17);1H

HIDE SMILES / InChI

Molecular Formula C14H20N2O3
Molecular Weight 264.3202
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Propacetamol is a bioprecursor of paracetamol. It is rapidly hydrolyzed by plasma esterases and releases its constituent paracetamol by the end of its intravenous or intramuscular administration. Its metabolism is identical to that of paracetamol. It is used in post-operative care and is delivered by I.V. It is given if the patient is unable to take oral or rectally delivered paracetamol and non-steroidal anti-inflammatory drugs are contraindicated. The onset of analgaesia from propacetamol is more rapid than paracetamol given orally. 2 g of propacetamol are equivalent to 1g of paracetamol.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
PRO-DAFALGAN
Primary
PRO-DAFALGAN

PubMed

Sample Use Guides

In Vivo Use Guide
Method of administration Intravenous route: Restricted to children weighing 33 kg or more and to adults. It is recommended to use the product immediately following reconstitution. Do not mix with other drugs because of the risk of incompatibility. Children weighing 33 kg or more Propacetamol is used in infusion over 15 minutes after dilution of the product, using a transfer device, in 5% glucose solution or 0.9% sodium chloride solution. In order to comply with blood volume, the maximum volume which may be infused in children is 1 to 2 ml/kg/injection. The 1 g powder should be dissolved in a 50 ml flexible bag. The 2 g powder should be dissolved in a 100 ml flexible bag. Adults After the product is reconstituted using the transfer device, administration takes place using 5% glucose solution or 0.9% sodium chloride solution (about 100 ml) over 15 minutes. Posology In children the posology is 30 mg/kg per injection, i.e. 1.5 ml/kg per injection of the 1 g solution reconstituted in 50 ml or the 2 g solution reconstituted in 100 ml, to be repeated if necessary after an interval of at least 6 hours, without exceeding the maximum daily posology of 120 mg/kg of propacetamol, i.e. 60 mg/kg of paracetamol. In adults the posology is 1 to 2 g, to be repeated if necessary after an interval of 4 hours, without exceeding 6 g per day, or in exeptional cases, 8 g per day. Frequency of administration Systematic administrations will avoid fluctuations of pain or fever. In children, they must be given at least 6 hours apart. In adults, they must be given at least 4 hours apart.
Route of Administration: Intravenous
In Vitro Use Guide
In hTRPV1-expressing cells 100 uM and higher concentrations activated membrane currents with a strong outward rectification in all cells which also generated capsaicin (1 uM)-induced currents
Substance Class Chemical
Record UNII
SH41QYH8E5
Record Status Validated (UNII)
Record Version